Drug intelligence / Profile preview

almitrine + dihydroergocristine

Development stage: Preclinical
Lead developer: Servier
Modality: Small Molecules
Administration: Oral

Overview

A combination drug consisting of almitrine and dihydroergocristine. Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. Dihydroergocristine is an ergot alkaloid with partial agonist activity on dopaminergic and alpha-adrenergic receptors and antagonist activity on serotonin receptors. This combination has been used for treating age-related cerebral disorders and cerebrovascular conditions.

Targets

5-HT2 (5-HT2 receptor family)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on almitrine + dihydroergocristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on almitrine + dihydroergocristine.

Explore the full profile